

SMARCA1

Purified Mouse Monoclonal Antibody Catalog # AO2533a

Product Information

Application	WB, IHC, ICC, E
Primary Accession	<u>P28370</u>
Reactivity	Human, Mouse
Host	Mouse
Clonality	Monoclonal
Clone Names	2H7B8
Isotype	Mouse IgG1
Calculated MW	121142
Calculated MW	121142
Immunogen	Purified recombinant fragment of human SMARCA1 (AA: 933-1070) expressed
Formulation	in E. Coli. Purified antibody in PBS with 0.05% sodium azide

Additional Information

Gene ID	6594
Other Names	SWI; ISWI; SWI2; SNF2L; SNF2L1; SNF2LB; SNF2LT; hSNF2L; NURF140
Dilution	WB~~ 1/500 - 1/2000 IHC~~ 1/200 - 1/1000 ICC~~N/A E~~ 1/10000
Storage	Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	SMARCA1 is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	SMARCA1 (<u>HGNC:11097</u>)
Synonyms	SNF2L, SNF2L1
Function	[Isoform 1]: ATPase that possesses intrinsic ATP-dependent chromatin-remodeling activity (PubMed: <u>14609955</u> , PubMed: <u>15310751</u> , PubMed: <u>15640247</u> , PubMed: <u>28801535</u>). ATPase activity is substrate- dependent, and is increased when nucleosomes are the substrate, but is also catalytically active when DNA alone is the substrate (PubMed: <u>14609955</u> , PubMed: <u>15310751</u> , PubMed: <u>15640247</u>). Catalytic subunit of ISWI chromatin-remodeling complexes, which form ordered nucleosome arrays on

	chromatin and facilitate access to DNA during DNA-templated processes such as DNA replication, transcription, and repair (PubMed: <u>14609955</u> , PubMed: <u>15310751</u> , PubMed: <u>15640247</u> , PubMed: <u>28801535</u>). Within the ISWI chromatin-remodeling complexes, slides edge- and center-positioned histone octamers away from their original location on the DNA template (PubMed: <u>28801535</u>). Catalytic activity and histone octamer sliding propensity is regulated and determined by components of the ISWI chromatin-remodeling complexes (PubMed: <u>28801535</u>). The BAZ1A-, BAZ1B-, BAZ2A- and BAZ2B-containing ISWI chromatin-remodeling complexes regulate the spacing of nucleosomes along the chromatin and have the ability to slide mononucleosomes to the center of a DNA template (PubMed: <u>28801535</u>). The CECR2- and RSF1-containing ISWI chromatin- remodeling complexes do not have the ability to slide mononucleosomes to the center of a DNA template (PubMed: <u>28801535</u>). Within the NURF-1 and CERF-1 ISWI chromatin remodeling complexes, nucleosomes are the preferred substrate for its ATPase activity (PubMed: <u>14609955</u> , PubMed: <u>15640247</u>). Within the NURF-1 ISWI chromatin-remodeling complex, binds to the promoters of En1 and En2 to positively regulate their expression and promote brain development (PubMed: <u>14609955</u>). May promote neurite outgrowth (PubMed: <u>14609955</u>). Facilitates nucleosome assembly during DNA replication, ensuring replication fork progression and genomic stability by preventing replication stress and nascent DNA gaps (PubMed: <u>39413208</u>).
Cellular Location	Nucleus. Chromosome
Tissue Location	[Isoform 1]: Expressed in lung, breast, kidney, ovary, skeletal muscle and brain.

References

1.Yonsei Med J. 2013 May 1;54(3):772-7.2.BMC Med Genet. 2008 Feb 26;9:11.

Images



Figure 1:Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)

Figure 2:Western blot analysis using SMARCA1 mAb against human SMARCA1 (AA: 933-1070) recombinant protein. (Expected MW is 42.4 kDa)



200

160

Counts 80 120

응

0-L 10⁰



Figure 4:Western blot analysis using SMARCA1 mouse mAb against SW620 (1) and HT-29 (2) cell lysate.





104

Figure 6:Immunohistochemical analysis of paraffin-embedded esophageal cancer tissues using SMARCA1 mouse mAb with DAB staining.



Figure 7:Immunohistochemical analysis of paraffin-embedded rectum cancer tissues using SMARCA1 mouse mAb with DAB staining.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.